Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana – ANA Abstract Submission NLP

October 17, 2016August 16, 2022 Alterity Therapeutics

final-ana-abstract-submission-nlp-4-8-16

2016

Post navigation

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Related Posts

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference

March 10, 2021August 16, 2022

New hope in global fight against antibiotic resistant superbugs

January 22, 2021August 16, 2022

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

September 30, 2024March 10, 2025

Recent Posts

Target Market Determination – Placement Offer
Target Market Determination – Broker Offer
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065